Bioactive lipids, LPC and LPA, are novel prometastatic factors and their tissue levels increase in response to radio/chemotherapy

Molecular Cancer Research

Volumn 12, Issue 11, 2014, Pages 1560-1573

  Schneider, Gabriela ^a   Sellers, Zachariah Payne ^a   Abdel Latif, Ahmed ^b   Morris, Andrew J ^b   Ratajczak, Mariusz Z ^a,c  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; VINCRISTINE; 3-(4-(4-((1-(2-CHLOROPHENYL)ETHOXY)CARBONYL AMINO)-3-METHYL-5-ISOXAZOLYL) BENZYLSULFANYL) PROPANOIC ACID; CHEMOTACTIC FACTOR; G PROTEIN COUPLED RECEPTOR; ISOXAZOLE DERIVATIVE; LYSOPHOSPHOLIPID; PROPIONIC ACID DERIVATIVE;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENIC ACTIVITY; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CELL SURVIVAL; ENZYME PHOSPHORYLATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GAMMA IRRADIATION; HUMAN; HUMAN CELL; IC50; METASTASIS; NONHUMAN; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA CELL LINE; TISSUE LEVEL; TREATMENT RESPONSE; ANIMAL; BONE MARROW; C57BL MOUSE; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; GAMMA RADIATION; METABOLISM; PATHOLOGY; RADIATION RESPONSE; RHABDOMYOSARCOMA; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; BONE MARROW; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CHEMOTACTIC FACTORS; DRUG RESISTANCE, NEOPLASM; GAMMA RAYS; HUMANS; ISOXAZOLES; LYSOPHOSPHATIDYLCHOLINES; LYSOPHOSPHOLIPIDS; MAP KINASE SIGNALING SYSTEM; MICE, INBRED C57BL; MICE, SCID; NEOPLASM METASTASIS; PROPIONATES; RECEPTORS, G-PROTEIN-COUPLED; RHABDOMYOSARCOMA; TUMOR MICROENVIRONMENT; VINCRISTINE;

EID: 84910670174     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0188     Document Type: Article

References (50)

1. Collins MH, Zhao H, Womer RB, Barr FG. Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusions. Med Pediatr Oncol 2001;37:83-9.
2. Sandberg AA, Stone JF, Czarnecki L, Cohen JD. Hematologic masquerade of rhabdomyosarcoma. Am J Hematol 2001;68:51-7.
3. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994;54:2869-72.
4. Schneider G, Bowser MJ, Shin DM, Barr FG, Ratajczak MZ. The paternally imprinted DLK1-GTL2 locus is differentially methylated in embryonal and alveolar rhabdomyosarcomas. Int J Oncol 2014;44: 295-300.
5. Libura J, Drukala J, Majka M, Tomescu O, Navenot JM, Kucia M, et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 2002;100: 2597-606.
6. Jankowski K, Kucia M,Wysoczynski M, Reca R, Zhao D, Trzyna E, et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but onlyHGFenhances their resistance to radiochemotherapy. Cancer Res 2003;63:7926-35.
7. Kalebic T, Tsokos M, Helman LJ. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res 1994;54:5531-4.
8. El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1990;1:325-31.
9. Ratajczak MZ, Lee H, Wysoczynski M,WanW, Marlicz W, Laughlin MJ, et al. Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia 2010; 24:976-85.
10. Kimura F, Miyazaki M, Suwa T, Sugiura T, Shinoda T, Itoh H, et al. Plasma human hepatocyte growth factor concentrations in patients with biliary obstruction. J Gastroenterol Hepatol 2000;15:76-82.
11. Schneider G, Bryndza E, Abdel-Latif A, Ratajczak J, Maj M, Tarnowski M, et al. Bioactive lipids S1P and C1P are prometastatic factors in human rhabdomyosarcoma, and their tissue levels increase in response to radio/chemotherapy. Mol Cancer Res 2013;11:793-807.
12. Ratajczak MZ, Jadczyk T, Schneider G, Kakar SS, Kucia M. Induction of a tumor-metastasis-receptive microenvironment as an unwanted and underestimated side effect of treatment by chemotherapy or radiotherapy. J Ovarian Res 2013;6:95.
13. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 2002;277:39436-42.
14. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002;158:227-33.
15. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010;50:157-86.
16. Kim C, Abdel-Latif A, Mierzejewska K, Schneider G, Sunkara M, Ratajczak J, et al. Ceramide-1-phosphate regulates migration of multipotent stromal cells (MSCs) and endothelial progenitor cells (EPCs)-implications for tissue regeneration. Stem Cells 2012; 31:500-10.
17. Grymula K, Tarnowski M, Wysoczynski M, Drukala J, Barr FG, Ratajczak J, et al. Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. Int J Cancer 2010;127:2554-68.
18. Federico L, Ren H, Mueller PA, Wu T, Liu S, Popovic J, et al. Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol 2012;26:786-97.
19. Fulkerson Z, Wu T, Sunkara M, Kooi CV, Morris AJ, Smyth SS. Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. J Biol Chem 2011; 286:34654-63.
20. Yoshida S, Fujisawa-Sehara A, Taki T, Arai K, Nabeshima Y. Lysophosphatidic acid and bFGF control different modes in proliferating myoblasts. J Cell Biol 1996;132:181-93.
21. Xu YJ, Tappia PS, Goyal RK, Dhalla NS. Mechanisms of the lysophosphatidic acid-induced increase in [Ca(2+)](i) in skeletal muscle cells. J Cell Mol Med 2008;12:942-54.
22. Yoon BK, Oh WJ, Kessel B, Roh CR, Choi D, Lee JH, et al. 17Betaestradiol inhibits proliferation of cultured vascular smooth muscle cells induced by lysophosphatidylcholine via a nongenomic antioxidant mechanism. Menopause 2001;8:58-64.
23. Matsumoto T, Kobayashi T, Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem 2007;14:3209-20.
24. Tania M, Khan MA, Zhang H, Li J, Song Y. Autotaxin: a protein with two faces. Biochem Biophys Res Commun 2010;401:493-7.
25. Ferry G, Moulharat N, Pradere JP, Desos P, Try A, Genton A, et al. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther 2008; 327:809-19.
26. Qiao J, Huang F, Naikawadi RP, Kim KS, Said T, Lum H. Lysophosphatidylcholine impairs endothelial barrier function through the G protein-coupled receptor GPR4. Am J Physiol Lung Cell Mol Physiol 2006;291:L91-101.
27. Khan SY, McLaughlin NJ, Kelher MR, Eckels P, Gamboni-Robertson F, Banerjee A, et al. Lysophosphatidylcholines activate G2A inducing G (alphai)(-)(1)-/G(alphaq/)(1)(1)-Ca(2)(+) flux, G(betagamma)-Hck activation and clathrin/beta-Arrestin-1/GRK6 recruitment in PMNs. Biochem J 2010;432:35-45.
28. Yuan L, Hu J, Luo Y, Liu Q, Li T, Parish CR, et al. Upregulation of heparanase in high-glucose-treated endothelial cells promotes endothelial cell migration and proliferation and correlates with Akt and extracellular-signal-regulated kinase phosphorylation. Mol Vis 2012;18:1684-95.
29. Shi Y, Xia YY, Wang L, Liu R, Khoo KS, Feng ZW. Neural cell adhesion molecule modulates mesenchymal stromal cell migration via activation of MAPK/ERK signaling. Exp Cell Res 2012;318:2257-67.
30. Kim D, Kim S, Koh H, Yoon SO, Chung AS, Cho KS, et al. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. Faseb J 2001;15:1953-62.
31. Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal KC. Upregulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res 2005;65:9891-8.
32. Kang MH, Smith MA, Morton CL, Keshelava N,Houghton PJ, Reynolds CP. National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 2011;56:239-49.
33. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 2011;11:597-606.
34. Tarnowski M, Grymula K, Liu R, Tarnowska J, Drukala J, Ratajczak J, et al. Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-Associated fibroblasts. Mol Cancer Res 2010;8:1328-43.
35. Xu X, Prestwich GD. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 2010;116:1739-50.
36. Gaetano CG, Samadi N, Tomsig JL, Macdonald TL, Lynch KR, Brindley DN. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Mol Carcinog 2009;48:801-9.
37. Hao F, Tan M, Xu X, Han J, Miller DD, Tigyi G, et al. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA (1), p42 and p38alpha. Biochim Biophys Acta 2007;1771:883-92.
38. Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, et al. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann N Y Acad Sci 2000;905:188-208.
39. Komachi M, Sato K, Tobo M, Mogi C, Yamada T, Ohta H, et al. Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo. Cancer Sci 2012;103: 1099-104.
40. Rivera-Lopez CM, Tucker AL, Lynch KR. Lysophosphatidic acid (LPA) and angiogenesis. Angiogenesis 2008;11:301-10.
41. Rikitake Y, Kawashima S, Yamashita T, Ueyama T, Ishido S, Hotta H, et al. Lysophosphatidylcholine inhibits endothelial cell migration and proliferation via inhibition of the extracellular signal-regulated kinase pathway. Arterioscler Thromb Vasc Biol 2000;20:1006-12.
42. Yanai N, Matsui N, Furusawa T, Okubo T, Obinata M. Sphingosine-1-phosphate and lysophosphatidic acid trigger invasion of primitive hematopoietic cells into stromal cell layers. Blood 2000;96:139-44.
43. Chiang CL, Chen SS, Lee SJ, Tsao KC, Chu PL, Wen CH, et al. Lysophosphatidic acid induces erythropoiesis through activating lysophosphatidic acid receptor 3. Stem Cells 2011;29:1763-73.
44. Ortlepp C, Steudel C, Heiderich C, Koch S, Jacobi A, Ryser M, et al. Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation. Exp Hematol 2013;41:444-61 e4.
45. Jing Q, Xin SM, Zhang WB, Wang P, Qin YW, Pei G. Lysophosphatidylcholine activates p38 and p42/44 mitogen-Activated protein kinases in monocytic THP-1 cells, but only p38 activation is involved in its stimulated chemotaxis. Circ Res 2000;87:52-9.
46. Samadi N, Bekele RT, Goping IS, Schang LM, Brindley DN. Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest. PLoS One 2011;6:e20608.
47. Ojala PJ, Hermansson M, Tolvanen M, Polvinen K, Hirvonen T, Impola U, et al. Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: a complementary role to albumin in the scavenging of lysophosphatidylcholine. Biochemistry 2006;45: 14021-31.
48. Croset M, Brossard N, Polette A, Lagarde M. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem J 2000;345 Pt 1:61-7.
49. Takuwa Y, Takuwa N, Sugimoto N. The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities. J Biochem 2002;131:767-71.
50. Kim CH, Wu W, Wysoczynski M, Abdel-Latif A, Sunkara M, Morris A, et al. Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors. Leukemia 2012;26:106-16.